2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl chloride | 845782-70-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl chloride
• 英文别名: 2-Phenyl-5-trifluoromethyl-oxazole-4-carbonyl chloride；2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carbonyl chloride
• CAS: 845782-70-9
• 化学式: C₁₁H₅ClF₃NO₂
• 分子量: 275.614
• InChiKey: UKTOUQCHJZMXFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl chloride 在 sodium hydroxide 、 水 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 1-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-piperidine-4-carboxylic acid
  参考文献：
  名称：

  WO2008/141976

  摘要：

  公开号：
• 作为产物：
  描述：

  2-苯基-5-(三氟甲基)唑-4-羧酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl chloride
  参考文献：
  名称：

  Inhibitors of Diacylglycerol Acyltransferase

  摘要：

  本文提供了至少含有四环结构的酰胺，这些酰胺是甘油二酰基转移酶的抑制剂，可用于治疗肥胖、2型糖尿病和代谢综合征等疾病。

  公开号：

  US20100152445A1

文献信息

• Diacylglycerol acyltransferase inhibitors
  申请人：Bolin Robert David

  公开号：US20070123504A1

  公开（公告）日：2007-05-31

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了式(I)的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如肥胖、2型糖尿病和代谢综合征等疾病是有用的。
• Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors
  申请人：Parker C. Janice

  公开号：US20050043292A1

  公开（公告）日：2005-02-24

  The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (“DPP-IV”), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

  该发明涉及新的具有治疗活性和选择性的酶二肽基肽酶-IV（“DPP-IV”）抑制剂，包括这些化合物的药物组合物以及利用这些化合物治疗与受DPP-IV加工的蛋白质相关的疾病，如2型糖尿病、代谢综合征（综合征X或胰岛素抵抗综合征）、高血糖、糖耐量受损、糖尿病、代谢性酸中毒、关节炎、白内障、糖尿病性神经病变、糖尿病性肾病、糖尿病性视网膜病变、糖尿病性心肌病、1型糖尿病、肥胖、由肥胖恶化的疾病、高血压、高脂血症、动脉粥样硬化、骨质疏松症、脆弱性、骨质流失、骨折、急性冠状动脉综合征、多囊卵巢综合征导致的不孕症、短肠综合征、焦虑、抑郁症、失眠、慢性疲劳、癫痫、进食障碍、慢性疼痛、酒精成瘾、与肠道蠕动有关的疾病、溃疡、肠易激综合征、炎症性肠病以及预防2型糖尿病疾病进展的方法。该发明还涉及一种用于识别糖尿病胰岛素分泌素的方法。
• Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors
  作者：Dong Jin Hong、Seung Hyun Jung、Jisook Kim、Danbee Jung、Young Gil Ahn、Kwee Hyun Suh、Kyung Hoon Min

  DOI：10.1080/14756366.2019.1693555

  日期：2020.1.1

  A novel series of thieno[3,2-d]pyrimidine derivatives were synthesised and their inhibitory effects against diacylglycerol acyltransferase 1 (DGAT-1) were assessed. cis-Isomer 17a showed potent and selective inhibitory activity against DGAT-1 in SF9 cells. In addition, 17a had an acceptable pharmacokinetic profile and accumulated mainly in the small intestine and liver. Oral administration of 17a led

  合成了一系列新的噻吩并[3,2-d]嘧啶衍生物，并评估了其对二酰基甘油酰基转移酶1（DGAT-1）的抑制作用。顺式异构体17a在SF9细胞中显示了对DGAT-1的有效和选择性抑制活性。另外，17a具有可接受的药代动力学特征，并且主要在小肠和肝脏中积累。在鼠和犬模型中进行口服脂质耐受性测试（OLTT）期间，口服17a导致血浆三酰甘油水平显着降低。两者合计，17a是一个高质量的候选对象，值得进一步研究。
• Diacylglycerol Acyltransferase Inhibitors
  申请人：Bolin David Robert

  公开号：US20090093497A1

  公开（公告）日：2009-04-09

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供的是公式(I)的化合物，以及其药物可接受的盐，其中取代基如规范中所述。这些化合物和含有它们的药物组合物对于治疗疾病，例如肥胖症、2型糖尿病和代谢综合征是有用的。
• Inhibitors of diacylglycerol acyltransferase
  申请人：Madrigal Pharmaceuticals, Inc.

  公开号：US08211914B2

  公开（公告）日：2012-07-03

  Provided herein are amides containing at least a four ring structure, which are inhibitors of diacylglycerol acyltransferase and are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供了至少含有四环结构的酰胺，它们是二酰基甘油酰基转移酶的抑制剂，并且可用于治疗疾病，例如肥胖症、2型糖尿病和代谢综合征。